| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_15fd9c73822ad80e38eec3673024869a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D411-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D411-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P41-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B57-00 |
| filingDate |
1994-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8ae6d301a9d0fdcd25c8d777feedb8d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb0a5af58c17ca2741c4f7de506d96ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_762a14f3edfd3b68ac19958f6fa1df8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67023a0d0a5cf3ba1318faeeb805ac4a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8a269f94309dc418820fb54bdce8c03 |
| publicationDate |
1999-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
GE-P19991705-B |
| titleOfInvention |
Derivatives of 1,3-Oxathiolan Nucleosidecis-4-Amino-1(2-hydroxymethyl-1,3-oxathiolane-5-yl)-(1H)-pyrimidine-2-one(-) enantiomer or its Salts or its Ester or Salts of Such Ester of (-)-Enantiomer and (+) – Enantiomer, Method for its Preparation, Pharmaceutical Composition thereof and Method for Treatment |
| abstract |
1.Technical Result Preparation of compounds with improved properties against human immunodeficiency viruses. 2.Essence A mixture of derivatives of oxathiolan nucleoside cis-4-amino-1(2-hydroxymethyl-1,3-oxathiolane-5-yl)-(1H)-pyrimidine-2-one (-)enan¬tiomer or its salts or its ester or salts of such ester are obtained by separating the mixture of (-)-enantiomer and (+)- enantiomer by means of chiral high efficiency liquid chromatography or enantio-selective catabolism which is conducted in the presence of ferments. Mixture of cis-4-amino-1(2-hydroxymethyl-1,3-oxathiolane-5-yl)-(1H)-pyrimi¬dine-2-one (-)enantiomer and (+)- enantiomer or their salts or their esters or salts of such ester in which (+)- enantiomer contents is no more than 5 mass % are obtained by separating the mixture of (-)-enantiomer and (+)- enantiomer comprising at least 5 mass % (+)- enantiomer by means of chiral high efficiency liquid chromatography or enantio-selective catabolism which is conducted in the presence of ferments. Antiviral composition in the form of active ingredient comprises the mentioned compounds in therapeutically effective amount. 3. Field of Application Organic chemistry, medicine. 6 ind., 12 dep. cl. 3 Tables. |
| priorityDate |
1990-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |